Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

The Coronary Drug Project was conducted between 1966 and 1975 to assess the long-term efficacy and safety of five lipid-influencing drugs in 8,341 men aged 30 to 64 years with electrocardiogram-documented previous myocardial infarction. The two estrogen regimens and dextrothyroxine were discontinued early because of adverse effects. No evidence of efficacy was found for the clofibrate treatment. Niacin treatment showed modest benefit in decreasing definite nonfatal recurrent myocardial infarction but did not decrease total mortality. With a mean follow-up of 15 years, nearly 9 years after termination of the trial, mortality from all causes in each of the drug groups, except for niacin, was similar to that in the placebo group. Mortality in the niacin group was 11% lower than in the placebo group (52.0 versus 58.2%; p = 0.0004). This late benefit of niacin, occurring after discontinuation of the drug, may be a result of a translation into a mortality benefit over subsequent years of the early favorable effect of niacin in decreasing nonfatal reinfarction or a result of the cholesterol-lowering effect of niacin, or both.

This article has been cited by other articles:

				J. M.S. Lee, M. D. Robson, L.-M. Yu, C. C. Shirodaria, C. Cunnington, I. Kylintireas, J. E. Digby, T. Bannister, A. Handa, F. Wiesmann, et al. Effects of high-dose modified-release nicotinic Acid on atherosclerosis and vascular function a randomized, placebo-controlled, magnetic resonance imaging study. J. Am. Coll. Cardiol., November 3, 2009; 54(19): 1787 - 1794. [Abstract] [Full Text] [PDF]

				R. Bitzur, H. Cohen, Y. Kamari, A. Shaish, and D. Harats Triglycerides and HDL Cholesterol: Stars or second leads in diabetes? Diabetes Care, November 1, 2009; 32(suppl_2): S373 - S377. [Full Text] [PDF]

				Z. Su, N. Ishimori, Y. Chen, E. H. Leiter, G. A. Churchill, B. Paigen, and I. M. Stylianou Four additional mouse crosses improve the lipid QTL landscape and identify Lipg as a QTL gene J. Lipid Res., October 1, 2009; 50(10): 2083 - 2094. [Abstract] [Full Text] [PDF]

				M. Miller Dyslipidemia and cardiovascular risk: the importance of early prevention QJM, September 1, 2009; 102(9): 657 - 667. [Abstract] [Full Text] [PDF]

				A. Meaney, G. Ceballos, J. Asbun, G. Solache, E. Mendoza, A. Vela, and E. Meaney The Vytorin on Carotid Intima-Media Thickness and Overall Arterial Rigidity (VYCTOR) Study J. Clin. Pharmacol., July 1, 2009; 49(7): 838 - 847. [Abstract] [Full Text] [PDF]

				N. Ren, R. Kaplan, M. Hernandez, K. Cheng, L. Jin, A. K. P. Taggart, A. Y. Zhu, X. Gan, S. D. Wright, and T.-Q. Cai Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74a/PUMA-G) J. Lipid Res., May 1, 2009; 50(5): 908 - 914. [Abstract] [Full Text] [PDF]

				I. Goldenberg, V. Boyko, A. Tennenbaum, D. Tanne, S. Behar, and V. Guetta Long-term Benefit of High-Density Lipoprotein Cholesterol-Raising Therapy With Bezafibrate: 16-Year Mortality Follow-up of the Bezafibrate Infarction Prevention Trial Arch Intern Med, March 9, 2009; 169(5): 508 - 514. [Abstract] [Full Text] [PDF]

				American Diabetes Association Standards of Medical Care in Diabetes--2009 Diabetes Care, January 1, 2009; 32(Supplement_1): S13 - S61. [Full Text] [PDF]

				J.-C. Fruchart, F. M Sacks, M. P Hermans, G. Assmann, W V. Brown, R. Ceska, M J. Chapman, P. M Dodson, P. Fioretto, H. N Ginsberg, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients Diabetes and Vascular Disease Research, November 1, 2008; 5(4): 319 - 335. [Abstract] [PDF]

				D J Hausenloy and D M Yellon Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels Postgrad. Med. J., November 1, 2008; 84(997): 590 - 598. [Abstract] [Full Text] [PDF]

				J. L. Rosenzweig, E. Ferrannini, S. M. Grundy, S. M. Haffner, R. J. Heine, E. S. Horton, and R. Kawamori Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3671 - 3689. [Abstract] [Full Text] [PDF]

				S. Lamon-Fava, M. R. Diffenderfer, P. H. R. Barrett, A. Buchsbaum, M. Nyaku, K. V. Horvath, B. F. Asztalos, S. Otokozawa, M. Ai, N. R. Matthan, et al. Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing Lipoproteins Arterioscler Thromb Vasc Biol, September 1, 2008; 28(9): 1672 - 1678. [Abstract] [Full Text] [PDF]

				M. J. Blaha, S. Bansal, R. Rouf, S. H. Golden, R. S. Blumenthal, and A. P. DeFilippis A Practical 'ABCDE' Approach to the Metabolic Syndrome Mayo Clin. Proc., August 1, 2008; 83(8): 932 - 943. [Abstract] [Full Text] [PDF]

				P. Toutouzas and D. Richter Carotid Intima--Media Thickness (cIMT): A Useful Clinic Tool or Research Luxury? Another View of the ENHANCE Trial Angiology, August 1, 2008; 59(2_suppl): 77S - 79S. [Abstract] [PDF]

				Z. T. Bloomgarden Cardiovascular Disease in Diabetes Diabetes Care, June 1, 2008; 31(6): 1260 - 1266. [Full Text] [PDF]

				D J Hausenloy and D M Yellon Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels Heart, June 1, 2008; 94(6): 706 - 714. [Abstract] [Full Text] [PDF]

				R. Movva and D. J. Rader Laboratory Assessment of HDL Heterogeneity and Function Clin. Chem., May 1, 2008; 54(5): 788 - 800. [Abstract] [Full Text] [PDF]

				M. Davidson, P. M. Meyer, S. Haffner, S. Feinstein, R. D'Agostino Sr, G. T. Kondos, A. Perez, Z. Chen, and T. Mazzone Increased High-Density Lipoprotein Cholesterol Predicts the Pioglitazone-Mediated Reduction of Carotid Intima-Media Thickness Progression in Patients With Type 2 Diabetes Mellitus Circulation, April 22, 2008; 117(16): 2123 - 2130. [Abstract] [Full Text] [PDF]

				J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1512 - 1524. [Full Text] [PDF]

				J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care, April 1, 2008; 31(4): 811 - 822. [Full Text] [PDF]

				R. B. Goldberg and T. A. Jacobson Effects of Niacin on Glucose Control in Patients With Dyslipidemia Mayo Clin. Proc., April 1, 2008; 83(4): 470 - 478. [Abstract] [Full Text] [PDF]

				G. Ferns and V. Keti HDL-cholesterol modulation and its impact on the management of cardiovascular risk Ann Clin Biochem, March 1, 2008; 45(2): 122 - 128. [Abstract] [Full Text] [PDF]

				R. Oh, A. Malani, H. Ammar, S. Mughal, and J. D. Brunzell Hypertriglyceridemia. N. Engl. J. Med., January 17, 2008; 358(3): 310 - 310. [Full Text] [PDF]

				E. M. deGoma, N. J. Leeper, and P. A. Heidenreich Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 49 - 55. [Abstract] [Full Text] [PDF]

				C. J. Lavie and R. V. Milani Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 56 - 58. [Full Text] [PDF]

				American Diabetes Association Standards of Medical Care in Diabetes--2008 Diabetes Care, January 1, 2008; 31(Supplement_1): S12 - S54. [Full Text] [PDF]

				J. D. Brunzell Hypertriglyceridemia N. Engl. J. Med., September 6, 2007; 357(10): 1009 - 1017. [Full Text] [PDF]

				I. M. Singh, M. H. Shishehbor, and B. J. Ansell High-Density Lipoprotein as a Therapeutic Target: A Systematic Review JAMA, August 15, 2007; 298(7): 786 - 798. [Abstract] [Full Text] [PDF]

				E. Windler, M. Schoffauer, and B.-C. Zyriax The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease Diabetes and Vascular Disease Research, June 1, 2007; 4(2): 136 - 142. [Abstract] [PDF]

				J. M S Lee and R. P Choudhury Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets Heart, May 1, 2007; 93(5): 559 - 564. [Abstract] [Full Text] [PDF]

				G. Yuan, K. Z. Al-Shali, and R. A. Hegele Hypertriglyceridemia: its etiology, effects and treatment Can. Med. Assoc. J., April 10, 2007; 176(8): 1113 - 1120. [Abstract] [Full Text] [PDF]

				B. C.H. Kwan, F. Kronenberg, S. Beddhu, and A. K. Cheung Lipoprotein Metabolism and Lipid Management in Chronic Kidney Disease J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1246 - 1261. [Full Text] [PDF]

				S. J. Nicholls, E. M. Tuzcu, I. Sipahi, A. W. Grasso, P. Schoenhagen, T. Hu, K. Wolski, T. Crowe, M. Y. Desai, S. L. Hazen, et al. Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis JAMA, February 7, 2007; 297(5): 499 - 508. [Abstract] [Full Text] [PDF]

				E. R. Bates, C. J. D. Babb, D. E. Casey, C. U. Cates, G. R. Duckwiler, T. E. Feldman, W. A. Gray, K. Ouriel, E. D. Peterson, K. Rosenfield, et al. ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (ACCF/SCAI/SVMB/SIR/ASITN Clinical Expert Consensus Document Committee on Carotid Stenting) Vascular Medicine, February 1, 2007; 12(1): 35 - 83. [PDF]

				American Society of Interventional & Therapeutic N, Society for Cardiovascular Angiography and Interve, Society for Vascular Medicine and Biology, Society of Interventional Radiology, E. R. Bates, J. D. Babb, D. E. Casey Jr, C. U. Cates, G. R. Duckwiler, T. E. Feldman, et al. ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (ACCF/SCAI/SVMB/SIR/ASITN Clinical Expert Consensus Document Committee on Carotid Stenting) J. Am. Coll. Cardiol., January 2, 2007; 49(1): 126 - 170. [Full Text] [PDF]

				C. Reasner Rational therapy of mixed dyslipidaemia in a patient with diabetes The British Journal of Diabetes & Vascular Disease, January 1, 2007; 7(1): 25 - 30. [Abstract] [PDF]

				A. S Wierzbicki Fibrates after the FIELD study: some answers, more questions Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 166 - 171. [Abstract] [PDF]

				S. R. Freeman, A. L. Drake, L. F. Heilig, M. Graber, K. McNealy, L. M. Schilling, and R. P. Dellavalle Statins, Fibrates, and Melanoma Risk: a Systematic Review and Meta-analysis. J Natl Cancer Inst, November 1, 2006; 98(21): 1538 - 1546. [Abstract] [Full Text] [PDF]

				P. Paramsothy and R. Knopp Management of dyslipidaemias. Heart, October 1, 2006; 92(10): 1529 - 1534. [Full Text] [PDF]

				H. Drexel Reducing risk by raising HDL-cholesterol: the evidence Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F23 - F29. [Abstract] [Full Text] [PDF]

				A. S. Wierzbicki Diabetic dyslipidaemia: the triad Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F30 - F33. [Abstract] [Full Text] [PDF]

				B. G. Brown Niaspan(R) in the management of dyslipidaemia: the evidence Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F60 - F67. [Abstract] [Full Text] [PDF]

				C. A. Reasner Achieving the therapeutic benefits of Niaspan(R) in daily practice Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F68 - F73. [Abstract] [Full Text] [PDF]

				A. J. Taylor Evidence to support aggressive management of HDL-cholesterol: implications of recent trials Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F74 - F80. [Abstract] [Full Text] [PDF]

				T. R Pedersen, G. Assmann, J.-P. Bassand, M J. Chapman, R. Erbel, and C. Sirtori Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment Diabetes and Vascular Disease Research, September 1, 2006; 3(2_suppl): S1 - S12. [Abstract] [PDF]

				J. Wittes A tale of three species rabbits, chickens and humans: an interview with clinical trials pioneer Jeremiah Stamler Clinical Trials, June 1, 2006; 3(3): 320 - 334. [PDF]

				K. L. Olson and L. A. Potts Role of the Pharmacist in the Management of Dyslipidemia Journal of Pharmacy Practice, April 1, 2006; 19(2): 94 - 102. [Abstract] [PDF]

				D. Duffy and D. J. Rader Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport Circulation, February 28, 2006; 113(8): 1140 - 1150. [Full Text] [PDF]

				P. J. Barter and J. J.P. Kastelein Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease J. Am. Coll. Cardiol., February 7, 2006; 47(3): 492 - 499. [Abstract] [Full Text] [PDF]

				R. Ohashi, H. Mu, X. Wang, Q. Yao, and C. Chen Reverse cholesterol transport and cholesterol efflux in atherosclerosis QJM, December 1, 2005; 98(12): 845 - 856. [Abstract] [Full Text] [PDF]

				2nd International Symposium on Triglycerides and HDL: Lipid abnormalities and their treatment Diabetes Care, November 1, 2005; 28(11): 2795 - 2802. [Full Text] [PDF]

				F. Espinosa-Larranaga, M. Vejar-Jalaf, and R. Medina-Santillan The importance of low serum levels of high-density lipoprotein cholesterol (HDL-C) as a cardiovascular risk factor Diabetes and Vascular Disease Research, October 1, 2005; 2(1_suppl): S1 - S8. [Abstract] [PDF]

				M. D. Ashen and R. S. Blumenthal Low HDL Cholesterol Levels N. Engl. J. Med., September 22, 2005; 353(12): 1252 - 1260. [Full Text] [PDF]

				J. Shepherd Raising HDL-cholesterol and lowering CHD risk: does intervention work? Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F15 - F22. [Abstract] [Full Text] [PDF]

				E. Bruckert, R. Pamphile, F. McCoy, and P. Andre Defining the prevalence of low HDL-C in a European cohort of dyslipidaemic patients Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F23 - F26. [Abstract] [Full Text] [PDF]

				J. J.P. Kastelein The realities of dyslipidaemia: what do the studies tell us? Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F27 - F33. [Abstract] [Full Text] [PDF]

				B. G. Brown Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F34 - F40. [Abstract] [Full Text] [PDF]

				C. A. Reasner Niaspan(R): a powerful treatment option for 'diabetic dyslipidaemia' Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F48 - F55. [Abstract] [Full Text] [PDF]

				M. R. Goldstein Use of Niacin During Non-ST-Segment Elevation Acute Coronary Syndromes JAMA, May 4, 2005; 293(17): 2092 - 2093. [Full Text] [PDF]

				J. M. Lee and R. P Choudhury ARBITER 2: targeting HDL to retard atherosclerosis progression: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2 The British Journal of Diabetes & Vascular Disease, March 1, 2005; 5(2): 78 - 80. [PDF]

				P. Barter Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus: The Pan-Asian Consensus Panel On Hdl-C The British Journal of Diabetes & Vascular Disease, March 1, 2005; 5(2_suppl): S1 - S15. [Abstract] [PDF]

				E. J. Whitney, R. A. Krasuski, B. E. Personius, J. E. Michalek, A. M. Maranian, M. W. Kolasa, E. Monick, B. G. Brown, and A. M. Gotto Jr. A Randomized Trial of a Strategy for Increasing High-Density Lipoprotein Cholesterol Levels: Effects on Progression of Coronary Heart Disease and Clinical Events Ann Intern Med, January 18, 2005; 142(2): 95 - 104. [Abstract] [Full Text] [PDF]

				J. Shepherd Raising HDL-C and lowering triglycerides: benefits beyond LDL-C modification The British Journal of Diabetes & Vascular Disease, January 1, 2005; 5(1_suppl): S12 - S16. [Abstract] [PDF]

				H. Drexel Modern intervention strategies for managing dyslipidaemia: the case for combination therapy The British Journal of Diabetes & Vascular Disease, January 1, 2005; 5(1_suppl): S17 - S23. [Abstract] [PDF]

				A. J. Taylor, L. E. Sullenberger, H. J. Lee, J. K. Lee, and K. A. Grace Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins Circulation, December 7, 2004; 110(23): 3512 - 3517. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Dyslipidemia and the Metabolic Syndrome Diabetes Care, December 1, 2004; 27(12): 3009 - 3016. [Full Text] [PDF]

				T I Metelitsina, J E Grunwald, J C DuPont, and G-S Ying Effect of niacin on the choroidal circulation of patients with age related macular degeneration Br J Ophthalmol, December 1, 2004; 88(12): 1568 - 1572. [Abstract] [Full Text] [PDF]

				E. A. Meagher Addressing Cardiovascular Disease in Women: Focus on Dyslipidemia J Am Board Fam Med, November 1, 2004; 17(6): 424 - 437. [Abstract] [Full Text] [PDF]

				S. H. Ganji, S. Tavintharan, D. Zhu, Y. Xing, V. S. Kamanna, and M. L. Kashyap Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells J. Lipid Res., October 1, 2004; 45(10): 1835 - 1845. [Abstract] [Full Text] [PDF]

				S. M. Grundy, J. I. Cleeman, C. N. Bairey Merz, H. B. Brewer Jr, L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith Jr, N. J. Stone, and Coordinating Committee of the National Cholesterol Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J. Am. Coll. Cardiol., August 4, 2004; 44(3): 720 - 732. [Abstract] [Full Text] [PDF]

				S. M. Grundy, J. I. Cleeman, C. N. B. Merz, H. B. Brewer Jr, L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith Jr, N. J. Stone, for the Coordinating Committee of the National Cho, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Arterioscler Thromb Vasc Biol, August 1, 2004; 24(8): e149 - e161. [Abstract] [Full Text] [PDF]

				S. M. Grundy, J. I. Cleeman, C. N. B. Merz, H. B. Brewer Jr, L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith Jr, N. J. Stone, for the Coordinating Committee of the National Cho, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation, July 13, 2004; 110(2): 227 - 239. [Abstract] [Full Text] [PDF]

				W. Insull Jr, M. E. McGovern, H. Schrott, P. Thompson, J. R. Crouse, F. Zieve, and J. Corbelli Efficacy of Extended-Release Niacin With Lovastatin for Hypercholesterolemia: Assessing All Reasonable Doses With Innovative Surface Graph Analysis Arch Intern Med, May 24, 2004; 164(10): 1121 - 1127. [Abstract] [Full Text] [PDF]

				J. McKenney New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders Arch Intern Med, April 12, 2004; 164(7): 697 - 705. [Abstract] [Full Text] [PDF]

				A. M. Gotto Jr and E. A. Brinton Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: A working group report and update J. Am. Coll. Cardiol., March 3, 2004; 43(5): 717 - 724. [Abstract] [Full Text] [PDF]

				M. E Mcgovern Review: Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome The British Journal of Diabetes & Vascular Disease, March 1, 2004; 4(2): 78 - 85. [Abstract] [PDF]

				M. K Ito The Metabolic Syndrome: Pathophysiology, Clinical Relevance, and Use of Niacin Ann. Pharmacother., February 1, 2004; 38(2): 277 - 285. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Aspects of Blood Pressure, Lipid, and Glycemic Treatment Diabetes Care, January 1, 2004; 27(1): 264 - 269. [Full Text] [PDF]

				C. D. Meyers, M. C. Carr, S. Park, and J. D. Brunzell Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia Ann Intern Med, December 16, 2003; 139(12): 996 - 1002. [Abstract] [Full Text] [PDF]

				S. Fazio and M. F. Linton Apolipoprotein AI as Therapy for Atherosclerosis: Does the Future of Preventive Cardiology Include Weekly Injections of the HDL Protein? Mol. Interv., December 1, 2003; 3(8): 436 - 440. [Abstract] [Full Text] [PDF]

				M. Miller Niacin as a Component of Combination Therapy for Dyslipidemia Mayo Clin. Proc., June 1, 2003; 78(6): 735 - 742. [Abstract] [PDF]

				B. T Yim and P. H Chong Niacin-ER and Lovastatin Treatment of Hypercholesterolemia and Mixed Dyslipidemia Ann. Pharmacother., January 1, 2003; 37(1): 106 - 115. [Abstract] [Full Text] [PDF]

				L. H. Kuller Hormone Replacement Therapy and Risk of Cardiovascular Disease: Implications of the Results of the Women's Health Initiative Arterioscler Thromb Vasc Biol, January 1, 2003; 23(1): 11 - 16. [Abstract] [Full Text] [PDF]

				References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]

				D. Grady, D. Herrington, V. Bittner, R. Blumenthal, M. Davidson, M. Hlatky, J. Hsia, S. Hulley, A. Herd, S. Khan, et al. Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II) JAMA, July 3, 2002; 288(1): 49 - 57. [Abstract] [Full Text] [PDF]

				W. S. Aronow Guest Editorial: Should Hypercholesterolemia in Older Persons Be Treated to Reduce Cardiovascular Events? J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2002; 57(7): M411 - 413. [Full Text]

				A. C. Boyonoski, J. C. Spronck, R. M. Jacobs, G. M. Shah, G. G. Poirier, and J. B. Kirkland Pharmacological Intakes of Niacin Increase Bone Marrow Poly(ADP-Ribose) and the Latency of Ethylnitrosourea-Induced Carcinogenesis in Rats J. Nutr., January 1, 2002; 132(1): 115 - 120. [Abstract] [Full Text] [PDF]

				L. Saucan and E. A. Brinton Lp A-I and Niacin: New Views of an Antiatherogenic Duo Arterioscler Thromb Vasc Biol, November 1, 2001; 21(11): 1707 - 1709. [Full Text] [PDF]

				T. Sakai, V. S. Kamanna, and M. L. Kashyap Niacin, but Not Gemfibrozil, Selectively Increases LP-AI, a Cardioprotective Subfraction of HDL, in Patients With Low HDL Cholesterol Arterioscler Thromb Vasc Biol, November 1, 2001; 21(11): 1783 - 1789. [Abstract] [Full Text] [PDF]

				H. Buchwald, A. M. Gotto Jr, and V. Fuster Risk Reduction and the Program on the Surgical Control of the Hyperlipidemias Response Circulation, August 28, 2001; 104 (9): e47 - e47. [Full Text] [PDF]

				M. C. Cheung, X.-Q. Zhao, A. Chait, J. J. Albers, and B. G. Brown Antioxidant Supplements Block the Response of HDL to Simvastatin-Niacin Therapy in Patients With Coronary Artery Disease and Low HDL Arterioscler Thromb Vasc Biol, August 1, 2001; 21(8): 1320 - 1326. [Abstract] [Full Text] [PDF]

				W. B. Parsons Jr., D. Waters, and R. R. Azar Niacin After Coronary Bypass Grafting and for Coronary Disease Prevention Circulation, July 10, 2001; 104 (2): e7 - e7. [Full Text] [PDF]

				A. I. Qureshi, M. F. K. Suri, L. R. Guterman, and L. N. Hopkins Ineffective Secondary Prevention in Survivors of Cardiovascular Events in the US Population: Report From the Third National Health and Nutrition Examination Survey Arch Intern Med, July 9, 2001; 161(13): 1621 - 1628. [Abstract] [Full Text] [PDF]

				A. M. Gotto Jr Primary Prevention of Coronary Heart Disease: Where Do We Go From Here? Arch Intern Med, April 9, 2001; 161(7): 922 - 924. [Full Text] [PDF]

				W. Wang, A. Basinger, R. A. Neese, B. Shane, S.-A Myong, M. Christiansen, and M. K. Hellerstein Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production Am J Physiol Endocrinol Metab, March 1, 2001; 280(3): E540 - E547. [Abstract] [Full Text] [PDF]

				M. F Muldoon, S. B Manuck, A. B Mendelsohn, J. R Kaplan, and S. H Belle Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials BMJ, January 6, 2001; 322(7277): 11 - 15. [Abstract] [Full Text] [PDF]